FOR IMMEDIATE RELEASE

Juva Life Granted First-of-Its-Kind License for Retail Cannabis Storefront in Redwood City, California

In Highly Competitive Process, Vertically Integrated California Cultivator and Life Science Research
Company Approved to Launch Brick-and-Mortar Location



VANCOUVER, British Columbia, April 6, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) ("Juva Life," "Juva" or the "Company"), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the Company's subsidiary, Juva Retail RWC Inc, was granted a license to operate a retail cannabis storefront in Redwood City, California, at 2301 Broadway. Juva was granted one of only four approvals allowing storefront retail cannabis businesses in commercial and mixed-use zones, following a rigorous and highly competitive application process.

"We thank the City of Redwood City for the care and attention they put to our retail storefront application, and we are honored that we have been awarded with the license," said Doug Chloupek, CEO and Founder of Juva. "The Juva retail storefront is a business milestone that we have strategically worked on for nearly two years. We look forward to providing our customers the same five-star service and best-in-class products we are known for offering through Juva Delivery at our new storefront location."

Redwood City has a four-phase cannabis program that was developed hand in hand with community support

following the state's legalization of adult-use cannabis sales in 2016. Phase I ensured the applications were complete,

Phase II involved critical evaluation and scoring, Phase III involved interviews and further scoring, and Phase IV was

the final City Manager Selection of chosen businesses.

The process included a rigorous, staff-led, merit-based application to ensure high-quality retail cannabis business

operators would be thoroughly reviewed and sufficiently qualified before receiving a permit. All applications for

cannabis storefront retail were required to provide relevant information, including neighborhood compatibility,

security and safety plans, and community benefits plans.

Juva Retail RWC Inc. was the highest-scoring applicant overall, being awarded a total of 1,876 points in Phase III,

which, when combined with the Company's Phase II score of 1,196 points, equals 3,072 points for a total score of

96%.

Additionally, Juva Life continues its focus on pharmaceutical and life sciences research, and is working to identify the

mode of action behind cannabis' anecdotal ability to control pain and inflammation. The Company recently identified

non-cannabinoid compounds JUVA-019 and JUVA-041, on which the Company has filed patent applications and has

conducted preclinical research showing that the compounds are effective as stand-alone compounds in inhibiting

inflammation by modulating certain biomarkers in the body. JUVA-019 and JUVA-041, which the Company has

nominated as lead drug candidates for further preclinical investigation, are currently advancing through phenotypic

models of chronic diseases of aging.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and

commercialize safe and effective cannabis products. The Company is leveraging multi-disciplinary research experts

across various fields standardization of cultivation, extraction, and formulation to offer consumers reproducible

medical benefits. Juva is building upon these natural product process chemistry skills, to now include discovery

pharmacology through a validated discovery technology platform. The Company will leverage revenue derived from

its retail operations to advance JUVA-019, JUVA-041, and other potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Juva is working to bring the cannabis market face to face with the

sector's next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may

constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking

information may include financial and other projections, as well as statements regarding future plans, objectives, or

economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking

statements can be identified by terms such as "may", "would", "could", "will", "likely", "except", "anticipate",

"believe", "intend", "plan", "forecast", "project", "estimate", "outlook", or the negative thereof or other similar

expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited

to, statements with respect to the objectives and business plans of the Company; product development,

commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the

actual results, performance or achievements of the Company to differ materially from any future results,

performance or achievements expressed or implied by the forward-looking information, including, without

limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to

retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as

well as all of the other risks as described in the Company's management discussion and analysis for year ended

December 31, 2020 under the heading "Risks and Uncertainties". Accordingly, readers should not place undue

reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the

date on which such statement is made. New factors emerge from time to time, and it is not possible for the

Company's management to predict all of such factors and to assess in advance the impact of each such factor on the

Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ

materially from those contained in any forward-looking information. The Company does not undertake any

obligation to update any forward-looking information to reflect information or events after the date on which it is

made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.